Relay Therapeutics, Inc. RLAY
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.35M | 10.68M | 15.36M | 8.36M | 8.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.35M | 10.68M | 15.36M | 8.36M | 8.36M |
| Cost of Revenue | 268.97M | 256.39M | 259.63M | 270.02M | 278.75M |
| Gross Profit | -258.62M | -245.71M | -244.28M | -261.67M | -270.40M |
| SG&A Expenses | 51.81M | 50.75M | 58.46M | 65.42M | 72.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 320.79M | 307.14M | 318.09M | 335.44M | 351.42M |
| Operating Income | -310.44M | -296.46M | -302.74M | -327.09M | -343.06M |
| Income Before Tax | -286.04M | -272.71M | -276.48M | -297.59M | -311.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -286.04 | -272.71 | -276.48 | -297.59 | -311.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -286.04M | -272.71M | -276.48M | -297.59M | -311.55M |
| EBIT | -310.44M | -296.46M | -302.74M | -327.09M | -343.06M |
| EBITDA | -308.22M | -293.61M | -299.18M | -322.79M | -338.15M |
| EPS Basic | -1.57 | -1.57 | -1.61 | -1.75 | -1.95 |
| Normalized Basic EPS | -0.98 | -0.98 | -1.01 | -1.09 | -1.22 |
| EPS Diluted | -1.57 | -1.57 | -1.61 | -1.75 | -1.95 |
| Normalized Diluted EPS | -0.98 | -0.98 | -1.01 | -1.09 | -1.22 |
| Average Basic Shares Outstanding | 728.49M | 696.91M | 686.29M | 680.22M | 648.06M |
| Average Diluted Shares Outstanding | 728.49M | 696.91M | 686.29M | 680.22M | 648.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |